OLT-induced HIRI results from the hypoxic insult produced by the disrupted blood flow followed by the subsequent reinitiation of blood flow that produces injurious immune and inflammatory responses. (2) This OLT-induced HIRI is a clinically significant disease process leading to microangiopathy, abnormal tissue perfusion, and eventual liver dysfunction. (3) To address the challenge of OLT-induced HIRI, exogenous transplantation of bone marrow-derived endothelial precursor cells (EPCs) has been shown to promote local angiogenesis through endothelial differentiation and release of angiogenic factors. (4) Moreover, exogenous transplantation of bone marrowderived EPCs has been shown to significantly improve liver regeneration and promote resolution of liver fibrosis. (4, 5) Additionally, growth factors have been shown to play important roles in liver regeneration after HIRI. (6) Therefore, combining the exogenous transplantation of bone marrow-derived EPCs with exogenous delivery of growth factors may provide a means by which to improve the in vivo function of EPCs in treating OLT-induced HIRI. Specifically, vascular endothelial growth factor (VEGF) has been identified as an important growth factor in promoting angiogenesis and has been shown to stimulate hepatocyte growth factor (HGF) expression, which functions to initiate liver regeneration. (7) On the basis of this evidence, we hypothesized that exogenous delivery of the VEGF gene prior to bone marrow-derived EPC transplantation may improve OLT-induced HIRI. In this study, we evaluated VEGF gene delivery as an adjunctive therapy to bone marrow-derived EPC transplantation in a rodent model of OLT-induced HIRI.
Materials and Methods

ETHICS STATEMENT
The experimental protocols of this study were approved by the Ethics Committee of the Second Affiliated Hospital of Chongqing Medical University (Chongqing, China). All animal procedures were carried out in accordance with the recommendations provided in the Guide for the Care and Use of Laboratory Animals (National Institutes of Health, Bethesda, MD). All surgical procedures were performed under ether anesthesia, and all efforts were made to minimize animal suffering.
For information on the following, please see the Supporting Information:
1. Isolation and cultivation of EPCs from rat bone marrow. 2. Identification of EPCs by fluorescent staining. 3. The 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay to assess EPC viability. 4. VEGF plasmid construction and amplification in E. coli (VEGF plasmid construction was performed as previously described). (8) 5. Preparation of VEGF Plasmid: Liposome complexes (preparation of the cationic DOTAP: Chol liposomes was performed as previously described).
6. OLT (an improved Kamada's 2-cuff method was applied for OLT between SD donor rats and Lewis rats (LEW) Wistar recipient rats as previously described with minor modifications). (10) 7. Liver transaminase assays (hepatic injury was assessed via liver transaminase activity as previously described). (11) 8. Western blotting (Western blotting was performed as previously described with minor modifications). (12) 9. analysis was performed as previously described with minor modifications). (13) (14) (15) 10. Assessment of nitric oxide synthase (NOS) and caspase 3 activity (NOS and caspase 3 activity were assayed as previously described). (16, 17) 11. Statistical analysis (statistical analyses were performed with SPSS, version 19 [IBM, Armonk, NY]).
Results
Prior to transplantation, EPCs were positively identified as dil-acetylated low-density lipoprotein positive (Dil-ac-LDL1)/Ulex europaeus agglutinin 1 positive (UEA-11) cells (Supporting Fig. 1 ). An MTT assay performed to confirm EPC viability prior to transplantation revealed robust EPC viability over 72 hours in vitro (Supporting Fig. 2 ). Post-VEGF gene delivery, we validated exogenous VEGF plasmid delivery to the liver tissue of the VEGF-treated groups (ie, the VEGF and EPC1VEGF groups) by fluorescent microscopy at 3 hours after reperfusion (Supporting Fig. 3 ). Next, we assessed endogenous hepatic expression of VEGF, vascular endothelial growth factor receptor (VEGFR)-1, and VEGFR-2 at 3 hours and 6 hours after reperfusion. The VEGF, EPC, and EPC1VEGF groups displayed significantly elevated VEGF, VEGFR-1, and VEGFR-2 expression relative to liposomal controls (LCONs; Supporting Fig. 4 ; Supporting Results). Moreover, the EPC1VEGF group showed significantly higher VEGF, VEGFR-1, and VEGFR-2 expression relative to both the VEGF and EPC groups (Supporting Fig. 4) .
Next, we assessed gross levels of hepatic injury by liver transaminase assays at 3 hours and 6 hours after reperfusion. Relative to LCONs, the VEGF, EPC, and EPC1VEGF groups displayed significantly lower alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels ( Fig. 1A,B ; Supporting Results). Moreover, the EPC1VEGF group displayed significantly lower ALT and AST levels relative to the VEGF and EPC groups ( Fig. 1A ,B; Supporting Results). Next, we assessed hepatocellular injury levels by Suzuki scoring at 3 hours and 6 hours after reperfusion. Relative to LCONs, the VEGF, EPC, and EPC1VEGF groups displayed significantly lower Suzuki scores ( Fig. 2A,B ; Supporting Information). Moreover, the EPC1VEGF group showed significantly lower Suzuki scores relative to the EPC and VEGF groups ( Fig. 2A,B ; Supporting Results).
Next, we assessed hepatic apoptosis levels by TUNEL staining at 3 hours and 6 hours after reperfusion. Relative to LCONs, the VEGF, EPC, and EPC1VEGF groups displayed significantly lower apoptosis levels ( Fig. 2C,D ; Supporting Results). Moreover, the EPC1VEGF group showed significantly lower apoptosis levels relative to the EPC and VEGF groups ( Fig. 2C,D ; Supporting Results). Having shown evidence of significant changes in apoptosis levels between the experimental groups, we next assayed several key biomarkers of apoptosis at 3 hours and 6 hours after reperfusion. First, relative to LCONs, the VEGF, EPC, and EPC1VEGF groups displayed significantly lower B cell lymphoma 2-associated X protein (BAX)/ B cell lymphoma 2 (BCL2) ratios-a p53-independent predictor of hepatic apoptosis activity ( Fig. 3A-C ; Supporting Results). (18) Moreover, the BAX/BCL2 ratio was significantly lower in the EPC1VEGF group relative to the EPC and VEGF groups ( Fig. 3A-C ; Supporting Results). These observed effects upon the Liver transaminase assays of (A) ALT and (B) AST were applied to assess gross hepatic injury at 3 hours and 6 hours after reperfusion. *P < 0.05 relative to NCON group; †P < 0.05 relative to SCON group; ‡P < 0.05 relative to LCON group; §P < 0.05 relative to VEGF group; ¶P < 0.05 relative to EPC group. BAX/BCL2 ratio were primarily driven through changes in BAX as opposed to BCL2 (Fig. 3A-C) . Second, relative to LCONs, the VEGF, EPC, and EPC1VEGF groups displayed a significantly lower activity of caspase 3-a proapoptotic "effector" caspase in liver tissue ( Fig. 3D; Supporting Results) . (19) Moreover, caspase 3 activity was significantly lower in the EPC1VEGF group relative to the VEGF and EPC groups at 3 hours after reperfusion ( Fig. 3D ; Supporting Results). Third, relative to LCONs, the VEGF, EPC, and EPC1VEGF groups displayed a significantly lower expression of heme oxygenase 1 (HO-1)-a repressor of apoptosis in hepatic tissue ( Fig. 3E ; Supporting Results). (20) However, HO-1 expression was not significantly different across the EPC1VEGF, EPC, and VEGF groups ( Fig. 3E ; Supporting Results). Fourth, relative to LCONs, the VEGF, EPC, and EPC1VEGF groups displayed a significantly lower expression of heat shock protein 70 (HSP70)-a chaperone protein that is up-regulated in response to stressinduced apoptosis in the liver ( Fig. 3F ; Supporting Results). (21) Moreover, HSP70 expression was significantly lower in the EPC1VEGF group relative to the EPC and VEGF groups at 3 hours after reperfusion ( Fig. 3F; Supporting Results) .
Next, we assessed the expression of 4 key hepatotrophic mitogens (ie, epidermal growth factor [EGF], heparin-binding epidermal growth factor-like growth factor [HB-EGF], HGF, and transforming growth factor a [TGF-a]) at 3 hours and 6 hours after reperfusion. (22) (23) (24) Relative to LCONs, the VEGF, EPC, and EPC1VEGF groups displayed significantly higher expression of EGF, HB-EGF, HGF, and TGF-a (Fig. 4A-D, Supporting Results) . Moreover, EGF, HB-EGF, and HGF expression were significantly higher in the EPC1VEGF group relative to the EPC and VEGF groups at 3 hours after reperfusion ( Fig.  4A-C ; Supporting Results), whereas TGF-a expression was significantly higher in the EPC1VEGF group relative to the EPC and VEGF groups at 6 hours after reperfusion (Fig. 4D, Supporting Results) .
Finally, we comparatively assessed VEGF-induced angiogenesis levels across the experimental groups. (25) By microscopic examination, all surgical groups showed local and sinusoidal bleeding (Fig. 5A) . Qualitatively, the EPC1VEGF group appeared to show greater liver sinusoidal endothelial cell (LSEC) proliferation and greater intact blood vessel wall formation relative to the EPC and VEGF groups (Fig. 5A) . Quantitatively, relative to LCONs, the VEGF, EPC, and EPC1VEGF groups displayed a significantly 
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larger number of vascular sections per field ( Fig. 5B ; Supporting Results). Moreover, the EPC1VEGF group displayed a significantly larger number of vascular sections per field relative to the EPC and VEGF groups ( Fig. 5B ; Supporting Results). With respect to endothelial nitric oxide synthase (eNOS) activity, relative to LCONs, the VEGF and EPC1VEGF groups displayed a significantly higher eNOS activity ( Fig. 5C ; Supporting Results). Moreover, the EPC1VEGF group displayed significantly higher eNOS activity relative to the EPC and VEGF groups at 3 hours after reperfusion ( Fig. 5C ; Supporting Results). With respect to inducible nitric oxide synthase (iNOS) activity, relative to LCONs, the VEGF, EPC, and EPC1VEGF groups displayed a significantly higher iNOS activity ( Fig. 5D ; Supporting Results). Moreover, the EPC1VEGF group displayed significantly higher iNOS activity relative to the EPC and VEGF groups at 3 hours after reperfusion (Fig. 5D , Supporting Results).
Discussion
Here, we evaluated exogenous VEGF gene delivery as an adjunctive therapy to bone marrow-derived EPC transplantation in a rodent model of OLT-induced HIRI. First, we found that VEGF gene delivery prior to EPC transplantation significantly enhances endogenous hepatic VEGF and VEGFR expression in post-OLT-induced HIRI. Second, we found that VEGF gene delivery prior to EPC transplantation significantly reduces hepatocellular injury in post-OLT-induced HIRI. Third, we found that VEGF gene delivery prior to EPC transplantation significantly reduces hepatic apoptosis levels as well as several key apoptosis biomarkers in post-OLT-induced HIRI. Fourth, we found that VEGF gene delivery prior to EPC transplantation significantly increases the expression of several potent hepatotrophic mitogens in post-OLT-induced HIRI. Finally, we found that VEGF gene delivery prior to EPC transplantation significantly increases angiogenesis and NOS activity in post-OLT-induced HIRI. On the basis of this evidence, exogenous liposomal delivery of the VEGF gene prior to bone marrow-derived EPC transplantation may be an effective strategy in decreasing OLT-induced HIRI. VEGF is a potent endothelial growth factor that has been shown to be expressed at low baseline levels in quiescent normal hepatocytes. (26) Following liver injury, both hepatocytes and HSCs have been shown to quickly up-regulate their VEGF secretion in response to cytokines as well as hypoxia in order to support hepatic recovery. (26) VEGF acts on its target cells via 2 key tyrosine kinase receptors named VEGFR-1 (alternatively fms related tyrosine kinase 1 [Flt-1]) and VEGFR2 (alternatively fetal liver kinase-1 [Flk-1] and kinase insert domain receptor [KDR] ). (27, 28) Because increased VEGF expression has been shown to be linked to both VEGFR-1 up-regulation on hepatocytes as well as VEGFR-1 and VEGFR-2 up-regulation on LSECs, (26) here we successfully confirmed the effective liposomal delivery of the VEGF gene to the target liver tissue of the VEGF-treated groups. Notably, although the VEGF and EPC1VEGF groups received identical doses of the VEGF plasmid, the EPC1VEGF group displayed significantly higher endogenous VEGF, VEGFR-1, and VEGFR-2 expression over the EPC group. This finding reveals that VEGF gene delivery prior to EPC transplantation enhances endogenous hepatic VEGF and VEGFR expression in post-OLT-induced HIRI.
The increased levels of hepatocellular apoptosis observed in HIRI are driven through several interrelated mechanisms. (29) For instance, the apoptosisassociated speck-like protein containing a caspase recruitment domain (ASC) associates with BAX to activate the proapoptotic p53/BAX pathway. activity also decreases antiapoptotic BCL2 expression while increasing proapoptotic caspase 3 expression. (30) In addition, HIRI also activates expression of HO-1 (also known as HSP32), which provides protection against HIRI through carbon monoxide (CO) generation. (31) Mechanistically, HO-1 promotes the expression of several antiapoptotic proteins through CO generation, including BCL2 and HSP70. (32, 33) Consistent with these findings, we found that OLT-induced HIRI increased hepatic apoptosis levels, the BAX/ BCL2 ratio, caspase 3 activity, HO-1 expression, and HSP70 expression. Notably, VEGF gene delivery prior to EPC transplantation was able to reduce hepatic apoptosis levels, the BAX/BCL2 ratio, caspase 3 activity, and HSP70 expression in post-OLT-induced HIRI. Although VEGF has been shown to induce BCL2 expression in endothelial cells, (34) further investigation is needed on the mechanism(s) by which VEGF modulates the expression of other apoptotic mediators in post-OLT-induced HIRI.
Quiescent normal hepatocytes display a wide array of receptors for growth factors. (35) Despite the expression of several growth factor receptors, evidence has defined a limited set of growth factors that actually function as direct hepatotrophic mitogens both in vitro and in vivo; these factors are the key EGFR ligands (ie, EGF, HB-EGF, and TGF-a) as well as HGF. (35) Therefore, here we only analyzed the expression of these 4 mitogens. VEGF stimulates hepatocyte proliferation through VEGFR-1-induced HGF up-regulation. (36, 37) Specifically, VEGF's binding to LSECs triggers the release of pro-HGF, which is then cleaved to form HGF. (31, 37) HGF then activates the release of TGF-a and other downstream signals that promote cell-cycle transition. (31) Moreover, VEGF's binding to LSECs also triggers the release of HB-EGF through an overlapping VEGFR-1/2-based mechanism. (37) Although VEGF has not been shown to directly upregulate EGF transcript expression through either VEGFR-1 or VEGFR-2, (37) VEGFR-1-expressing macrophages secrete EGF and increasing VEGFR-1 signaling has been shown to up-regulate EGF expression in VEGF-stimulated macrophages. (27) Consistent with this evidence, we observed that VEGF gene delivery prior to EPC transplantation was able to increase the expression of all 4 hepatotrophic factors (ie, EGF, HB-EGF, HGF, and TGF-a) in post-OLT-induced HIRI.
VEGF has been well established as an angiogenic factor, as it promotes endothelial cell proliferation as well as the expression of various proteases that enable new blood vessel formation. (26) As VEGFR-2 activation by VEGF promotes LSEC proliferation, normal VEGF-induced angiogenesis is held to be mediated by VEGFR-2, whereas VEGFR-1 activation can lead to dysfunctional angiogenesis. (26, 27) Moreover, VEGFR-2 activation (as opposed to VEGFR-1 activation) by VEGF has been shown to up-regulate the proangiogenic NO-producing enzymes eNOS and iNOS. (38) Consistent with this evidence, VEGF gene delivery prior to EPC transplantation increased vascular formation and NOS activity in post-OLTinduced HIRI.
In conclusion, exogenous liposomal delivery of the VEGF gene prior to bone marrow-derived EPC transplantation may be an effective strategy in decreasing OLT-induced HIRI. Further research with various VEGF delivery models in combination with EPC transplantation in other animal models of OLTinduced HIRI are warranted.
